Gram-positive bacteria

Laboratory Analysis of the ePlex® Blood Culture Identification Panels for Timelier Diagnosis of Gram-Negative and Gram-Positive Bacteremia, Webinar Hosted by Xtalks

Retrieved on: 
Thursday, November 19, 2020
Branches of biology, Medical specialties, Bacteriology, Bacterial diseases, Blood culture, Microbiology, Bloodstream infections, Medical microbiology, Gram-positive bacteria, Bacteria, Enterobacter cloacae

Molecular techniques are now an important tool in the clinical microbiology laboratory to provide organism and resistance-mechanism identification quickly using rapid multiplex panels.

Key Points: 
  • Molecular techniques are now an important tool in the clinical microbiology laboratory to provide organism and resistance-mechanism identification quickly using rapid multiplex panels.
  • These panels can be used directly on positive blood cultures to deliver information to clinicians for timelier management of patients with bloodstream infections due to bacterial and fungal pathogens.
  • In this webinar, the audience will hear a microbiology laboratory director and an infectious diseases physician from a tertiary care facility describe their experience testing positive blood cultures from the clinical microbiology laboratory on the ePlex Blood Culture Identification Gram-Negative and Gram-Positive Panels.
  • For more information, or to register for this event, visit Laboratory Analysis of the ePlex Blood Culture Identification Panels for Timelier Diagnosis of Gram-Negative and Gram-Positive Bacteremia.

Antibacterial Properties of OsteoFab® PEKK Implants Defined in New Research, Outperforming PEEK and Titanium

Retrieved on: 
Wednesday, November 18, 2020
Chemistry, Medical specialties, Articles, Gram-positive bacteria, Polyetherketoneketone, Polyethers, Thermoplastics, Healthcare-associated infections, Staphylococcus epidermidis, Methicillin-resistant Staphylococcus aureus, Proteoglycan 4, Titanium

This was true for all tested bacteria strains, which included S. epidermidis, P. aeruginosa, and MRSA, and all tested materials, as 3D printed PEKK significantly outperformed commercially available titanium and PEEK controls.

Key Points: 
  • This was true for all tested bacteria strains, which included S. epidermidis, P. aeruginosa, and MRSA, and all tested materials, as 3D printed PEKK significantly outperformed commercially available titanium and PEEK controls.
  • As expected, the experiment showed greater protein adsorption of lubricin, mucin, and casein on PEKK in comparison to PEEK and titanium controls.
  • This greater protein adsorption was then correlated to greater bacteria inhibition of 3D printed PEKK compared to commercially available PEEK and titanium.
  • This finding is extremely important as it provides objective evidence explaining why OPM's 3D printed PEKK exhibits inherent antibacterial effects.

DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020

Retrieved on: 
Thursday, November 12, 2020
Medical specialties, Clostridiaceae, Gram-positive bacteria, Microbiology, Infectious diseases, Antibiotic-resistant bacteria, Clostridioides difficile, CDI, Clostridioides, COVID-19 pandemic

Patients enrollment is ongoing in this Phase II trial despite a disrupted context due to the COVID-19 outbreak.

Key Points: 
  • Patients enrollment is ongoing in this Phase II trial despite a disrupted context due to the COVID-19 outbreak.
  • 40% of patients suffering a Clostridioides difficile infection (CDI) have severe forms, associated with high morbidity and mortality rates.
  • DEINOVE is a French biotech company, a pioneer in the exploitation of the unknown or little-known part of biodiversity.
  • DEINOVE, located in the Euromdecine science park in Montpellier, employs 56 people, mainly researchers, engineers and technicians, and has filed over 350 patent applications internationally.

Galmed and MyBiotics to Collaborate in Development of Bespoke Microbiome Signature for Aramchol

Retrieved on: 
Monday, November 9, 2020
Bacteria, Medical specialties, Microbiology, Clostridiaceae, Gram-positive bacteria, Antibiotic-resistant bacteria, Clostridioides difficile, Clostridium difficile, Clostridium, Steatohepatitis, Microbiome

The research will also focus on development of a standalone microbiome-based treatment for non alcoholic steatohepatitis (NASH) and fibrosis.

Key Points: 
  • The research will also focus on development of a standalone microbiome-based treatment for non alcoholic steatohepatitis (NASH) and fibrosis.
  • MyBiotics' microbiome therapeutic technology enables the design of bespoke microbial consortia profiles based on MyBiotics' unique culturing and fermentation capabilities.
  • MyBiotics' lead product candidate for treatment of recurring clostridium difficile infection (CDI), MBX-SD-202, is expected to enter Phase I clinical trials in 2021.
  • "The collaboration, which aims to elevate the response rate of Aramchol, is part of our overall plan to maximize Aramchol clinical efficacy.

Finch Therapeutics Presents Data from Its Positive PRISM3 Trial of CP101 in Recurrent C. difficile Infection at Two Leading Medical Conferences

Retrieved on: 
Wednesday, October 28, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Microbiology, Medical specialties, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Branches of biology, CP101, Finch Therapeutics

The data presented expand on the positive topline results previously reported from PRISM3, a randomized, placebo-controlled, multi-center, Phase 2 trial, which demonstrated that CP101 met the primary efficacy endpoint with a statistically significant improvement in the prevention of recurrent CDI compared to placebo.

Key Points: 
  • The data presented expand on the positive topline results previously reported from PRISM3, a randomized, placebo-controlled, multi-center, Phase 2 trial, which demonstrated that CP101 met the primary efficacy endpoint with a statistically significant improvement in the prevention of recurrent CDI compared to placebo.
  • CP101 is an investigational, orally administered microbiome drug that Finch is developing for conditions linked to microbiome dysfunction.
  • CP101 is in late-stage clinical development for the prevention of recurrent C. difficile infection.
  • Finchs Human-First Discovery platform enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms.

AseptiScope Announces that Data Presented at October Medical Congresses Support the Use of Aseptic Disk Covers to Protect Against Contaminated Stethoscopes

Retrieved on: 
Thursday, October 22, 2020
Medical specialties, Microbiology, Branches of biology, Clostridiaceae, Gram-positive bacteria, Medical equipment, Sound technology, Stethoscope, Asepsis, Barrier isolator, Clostridioides difficile, Clostridioides

Dr. Frank Peacock, a co-founder of AseptiScope and a co-author of the study featured at the IDSA entitled Effectiveness of Aseptic Stethoscope Barriers in Allowing Clean Contact for Clostridioides Difficile-Contaminated Stethoscope, commented "this important study builds on a body of data supporting the use of aseptic disk covers to protect patients from exposure to pathogens on the stethoscope.

Key Points: 
  • Dr. Frank Peacock, a co-founder of AseptiScope and a co-author of the study featured at the IDSA entitled Effectiveness of Aseptic Stethoscope Barriers in Allowing Clean Contact for Clostridioides Difficile-Contaminated Stethoscope, commented "this important study builds on a body of data supporting the use of aseptic disk covers to protect patients from exposure to pathogens on the stethoscope.
  • "We are pleased to see these two prestigious congresses focus on the longstanding challenge of stethoscope hygiene," said Scott Mader the CEO and co-founder of AseptiScope.
  • "The findings further substantiate the stethoscope contamination challenge while supporting the use and effectiveness of touch-free, aseptic, single-use stethoscope disk covers.
  • With the upcoming launch of our flagship product, The DiskCover System, we look forward to bringing important innovation to this market," he added.

Recce Pharmaceuticals Receives Ethics Approval to Start Phase I/II Study Evaluating Topical Spray-On Synthetic Antibiotic RECCE® 327 on Chronic Burn Wounds

Retrieved on: 
Monday, October 19, 2020
Articles, Health, Branches of biology, Pharmaceuticals policy, Veterinary medicine, Antimicrobial resistance, Evolutionary biology, Antibiotic, Gram-positive bacteria

Human ethics approval is another milestone for Recce and the clinicians seeking effective treatments to combat the scourge of antibiotic resistant bacteria, said Recce Pharmaceuticals Chairman Dr. John Prendergast.

Key Points: 
  • Human ethics approval is another milestone for Recce and the clinicians seeking effective treatments to combat the scourge of antibiotic resistant bacteria, said Recce Pharmaceuticals Chairman Dr. John Prendergast.
  • The Phase I/II topical study will assess RECCE 327 as a broad-spectrum antibiotic for patients with Gram-positive and Gram-negative bacterial burn wound infections.
  • Burn wounds specialists will oversee delivery of RECCE 327 via a spray-on formulation, specially developed for the study.
  • This ethics approval is confirmation Recce has completed the necessary pre-clinical safety and efficacy testing of RECCE 327 required to commence human clinical trials.

COVID-19 Recovery Analysis: Clostridium Difficile Treatment Market |Tentative Approval Of Late Stage Molecules to Boost the Market Growth | Technavio

Retrieved on: 
Monday, September 21, 2020
Health, Other Health, Clostridiaceae, Gram-positive bacteria, Microbiology, Branches of biology, Physical sciences, Clostridium, Pathogenic bacteria, Clostridioides difficile, Copper

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • View the full release here: https://www.businesswire.com/news/home/20200921005447/en/
    Technavio has announced its latest market research report titled Global Clostridium Difficile Treatment Market 2020-2024 (Graphic: Business Wire)
    Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied.
  • Tentative approval of late stage molecules has been instrumental in driving the growth of the market.
  • Download a Free Sample Report on COVID-19 Impacts
    Clostridium Difficile Treatment Market 2020-2024: Segmentation
    Clostridium Difficile Treatment Market is segmented as below:

United Methicillin Resistant Staphylococcus Aureus (MRSA) Infections Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 18, 2020
Infectious diseases, Pharmaceutical, Health, Medical specialties, Microbiology, Branches of biology, Bacteriology, Gram-positive bacteria, Pathogenic bacteria, Staphylococcus aureus, Methicillin, Tefibazumab, Staphefekt

The "US Methicillin Resistant Staphylococcus Aureus Infections Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Methicillin Resistant Staphylococcus Aureus Infections Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • US Methicillin Resistant Staphylococcus Aureus Infections Market and Competitive Landscape Highlights - 2020, provides comprehensive insights into Methicillin Resistant Staphylococcus Aureus Infections pipeline products, Methicillin Resistant Staphylococcus Aureus Infections epidemiology, Methicillin Resistant Staphylococcus Aureus Infections market valuations and forecast, Methicillin Resistant Staphylococcus Aureus Infections drugs sales and competitive landscape in the US.
  • Methicillin Resistant Staphylococcus Aureus Infections pipeline: Find out the products in clinical trials for the treatment of Methicillin Resistant Staphylococcus Aureus Infections by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Methicillin Resistant Staphylococcus Aureus Infections epidemiology: Find out the number of patients diagnosed (prevalence) with Methicillin Resistant Staphylococcus Aureus Infections in the US
    Methicillin Resistant Staphylococcus Aureus Infections drugs: Identify key products marketed and prescribed for Methicillin Resistant Staphylococcus Aureus Infections in the US, including trade name, molecule name, and company
    Methicillin Resistant Staphylococcus Aureus Infections drugs sales: Find out the sales revenues of Methicillin Resistant Staphylococcus Aureus Infections drugs in the US
    Methicillin Resistant Staphylococcus Aureus Infections market valuations: Find out the market size for Methicillin Resistant Staphylococcus Aureus Infections drugs in 2019 in the US.
  • Find out how the market advanced from 2016 and forecast to 2025
    Methicillin Resistant Staphylococcus Aureus Infections drugs market share: Find out the market shares for key Methicillin Resistant Staphylococcus Aureus Infections drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Methicillin Resistant Staphylococcus Aureus Infections products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200918005395/en/

Research Study Finds Doctor's Biome Colon Health™ Completely Inhibits the Life-Threatening C. diff.

Retrieved on: 
Wednesday, September 9, 2020
Medical specialties, Microbiology, Clostridiaceae, Gram-positive bacteria, Branches of biology, Bacteriology, Antibiotic-resistant bacteria, Clostridioides difficile, Digestive system, Probiotic, Clostridium difficile, Clostridium

"This is an exciting finding which will be the basis of our upcoming clinical trial to show the safety and efficacy of Doctor's Biome Colon Health against Clostridium difficile Infection (CDI).

Key Points: 
  • "This is an exciting finding which will be the basis of our upcoming clinical trial to show the safety and efficacy of Doctor's Biome Colon Health against Clostridium difficile Infection (CDI).
  • "Said Dr. Howard F. Robins, Founder and Chief Medical Officer of Doctor's Biome.
  • What makes Doctor's Biome Colon Health (DBCH) different from other probiotics?
  • Every batch ofDoctor's Biome Colon Healthis tested by an independent, FDA-registered accredited microbiology lab for safety (absence of pathogens).